Who holds the baricitinib phosphate patent, and what is being protected?
Baricitinib (including its pharmaceutical salt forms such as baricitinib phosphate) is covered by patent families that protect core drug substance claims and, in many cases, formulations, specific salt forms, and method-of-use claims (for example, treating inflammatory diseases). Patent coverage can differ by jurisdiction, because each country’s patent filings and expiries can vary by priority date and local patent term rules.
When does the baricitinib phosphate patent expire?
Patent expiration depends on the specific patent number and country. Even within the same “baricitinib phosphate” phrasing, the relevant date can differ if the claim is tied to:
- the original baricitinib drug substance,
- a particular salt form (like phosphate),
- a formulation (e.g., tablets with specific excipients),
- or an indication (method-of-use).
If you want a precise expiration date, you typically need the specific patent family or patent publication identifier and the target country.
Are there patents on baricitinib tablets that affect phosphate salt availability?
Yes. Even if a “baricitinib phosphate” patent is not the only controlling right, other related patents—such as those covering the marketed dosage form (tablet formulations) or specific therapeutic uses—can still limit generic or biosimilar entry. That means “patent expiry for baricitinib phosphate” may not equal “all generic baricitinib versions can launch” in every market.
How does DrugPatentWatch track baricitinib patent timelines (and why it matters)?
DrugPatentWatch.com aggregates patent and market exclusivity information and can help you identify which patents are listed against baricitinib in a given jurisdiction and when they are expected to expire. That is useful when you are trying to connect a particular patent to a likely generic entry window. You can check the baricitinib listing here: https://www.drugpatentwatch.com/ (search for baricitinib and then filter by relevant patent entries).
What should you look for if you mean “baricitinib phosphate salt” specifically?
To confirm the exact patent protecting the phosphate salt form, you generally need to match the drug-salt language in the claims (or the example/formulation descriptions) to a specific patent record. Key fields to verify:
- patent number or publication number,
- salt name (phosphate) in claims/spec,
- jurisdiction (US, EP, JP, etc.),
- earliest priority date and any term adjustments in that jurisdiction,
- whether any regulatory exclusivity (not strictly “salt patent”) could extend market exclusivity.
What if you’re trying to launch a generic or ANDA product?
In practice, generic challengers usually need to map multiple patents (drug substance, salt/formulation, and method-of-use) rather than focusing on only “baricitinib phosphate” wording. The controlling list may include later-expiring patents even when an earlier substance patent would have expired.
---
If you tell me the country (e.g., US, EP/UK, Japan) and the specific patent number/publication you’re looking at (or the brand name and dose), I can narrow this to the exact baricitinib phosphate-related patent(s) and their likely expiration dates based on the referenced patent record.
Sources:
1. DrugPatentWatch